Many cancers are considered the highly lethal diseases, contributing to continuously increased health and economic burden worldwide. [1][2][3][4] Although the research and treatment for these highly lethal cancers progresses rapidly, the outcome is still disappointing. There are many reasons that can explain the causes about the worse outcomes of these highly lethal cancers. Delayed diagnosis and diagnosis at the advanced stage may be one of the most critical causes, since these highly lethal disease often present vague and nonspecific symptoms, and sometimes totally free of symptoms or late onset of clinical symptoms of these diseases, and additionally, clinically, the lack of efficient disease markers and absence of cost-effectiveness and friendly or convenient screening methods can be used for general population and even for high-risk population. All result in the loss of change to cure these diseases during their early stage status. 1-4 Among these cancers, esophageal cancer (EC) is frequently discussed, since advanced EC either as squamous cell carcinoma (SCC) type or adenocarcinoma types has a very poor prognosis with a 5-year overall survival rate less than 20%. 5 To overcome the big gap between an early identification of cancers at the early stage in theory and a late diagnosis of cancers at the advanced stage in the real world, it is urgent to use an effective screening tool or apply the effective preventive strategy for these highly lethal diseases. With continuous progress of biotechnology, the results of some are relatively promising. These strategies include the development of novel blood biomarkers, the advanced technology of diagnostic tools such as endoscopy and artificial intelligence-assisted endoscopy in the diagnostic work-up of precancer and cancer lesions of esophagus (esophageal intraepithelial neoplasm [EIN] and EC). 5 Blood biomarkers for EIN or EC have been investigated for many years, and with